Company intelligence / Profile preview

EDP Consulting

Knoxville, Tennessee, United Statesedpci.com ↗

Ownership: Private
Development stage: Other

Overview

The company's first commercial product, ColoPlex™, enables early detection of colorectal cancers and pre-cancerous polyps through a multi-marker blood test. The company also provides CRO services supporting IVD device development and validation. Following its merger with New Day Diagnostics in July 2023, the combined entity expanded its pipeline into DTC celiac disease testing and other oncology/infectious disease diagnostics.

Therapeutic areas: OncologyInfectious Diseases
Modalities: In vitro diagnostic assayMonoclonal antibody-based detection methodsMultiplex assaysSmall molecule detection via blood tests
Industry: Protein Biomarker Diagnostics

Partnerships

Strategic partnerships through CRO servicesNow merged with New Day Diagnostics

Beyond the preview

Go deeper on EDP Consulting.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP Consulting.

Explore the full profile